Hay fever is seasonal, predictable and enormous — which is exactly why it draws telehealth operators, and exactly why it is easy to run as a lazy supply funnel. Most allergic rhinitis is managed with treatments people can already buy; the value a service adds is structured step-up care, honest referral limits, and refusing the shortcuts that sit outside guidance. Here is how to build one properly.
Why allergy suits telehealth
Seasonal allergic rhinitis is a good telehealth fit: patients usually know their pattern, the treatment ladder is well established, and demand spikes predictably each spring and summer. A service can assess control, step treatment up or down, and review without a clinic visit.
The commercial model is a light-touch subscription or seasonal course. The honest framing is that much of the treatment is available over the counter, so the service has to add genuine clinical value — assessment, escalation and safety — rather than simply charging to post antihistamines.
The treatment ladder
Allergic rhinitis is managed by stepping up as needed:
- Oral antihistamines — non-sedating options such as cetirizine, loratadine and fexofenadine.
- Intranasal corticosteroids — such as beclometasone or fluticasone, the mainstay for moderate-to-severe nasal symptoms.
- Antihistamine or anti-inflammatory eye drops for allergic conjunctivitis.
- Combination and higher-intensity regimens where single agents are not controlling symptoms.
Guidance from sources such as NICE Clinical Knowledge Summaries and BSACI frames this ladder. Choice depends on symptom pattern, severity and response — prescriber discretion applies.
What needs a prescription vs pharmacy
A large share of allergy treatment is available as pharmacy (P) or general-sale products — many antihistamines and some intranasal steroids can be bought without a prescription. That shapes the model: for straightforward cases the service's value is advice and the right product, not a prescription.
Prescribing comes into play for less-responsive symptoms, higher-intensity or combination treatment, and cases needing clinical oversight. Being clear about that line — where over-the-counter care ends and prescribing begins — keeps the service honest and avoids medicalising what a pharmacist could handle.
Much of allergy treatment can be bought over the counter, so a telehealth service earns its place through assessment, step-up care and safety — not by charging to post antihistamines. Where over-the-counter care ends and prescribing begins should be an explicit line, not a blur.
The Kenalog question: depot steroid injections
A recurring demand in private hay fever is the depot corticosteroid injection (often known by the brand Kenalog). It is worth being direct: routine use of depot steroid injections for hay fever is not recommended in UK guidance, because the risk profile of a systemic long-acting steroid outweighs the benefit for a self-limiting seasonal condition.
A responsible service does not offer treatments that sit outside guidance simply because patients ask and will pay. Declining them, and explaining why, is part of what separates a clinical service from a demand-led one — prescriber discretion and current guidance govern this.
Red flags: anaphylaxis and when to refer
Allergy carries genuine emergencies. A history of anaphylaxis is not a remote-hay-fever patient: it needs proper allergy assessment, an adrenaline auto-injector where indicated, and specialist input. Poorly controlled asthma alongside allergic rhinitis, or symptoms not responding to appropriate treatment, are also signals to escalate rather than keep prescribing.
Clinicians need clear thresholds for taking someone out of the routine pathway and toward urgent or specialist care, and immunotherapy is a specialist service, not a remote add-on. Document those decisions. A service that treats every allergy the same is missing the ones that matter.
A responsible service does not offer treatments that sit outside guidance because patients ask and will pay. Declining the depot steroid injection for hay fever, and explaining why, is what separates a clinical service from a demand-led one.
Building a seasonal service
Operationally, allergy is a seasonal surge business: demand concentrates, so the assessment, prescriber capacity and fulfilment have to scale up and down cleanly. Underneath sits the same regulated spine as any prescribing vertical — identity, prescriber governance, dispensing and safety-netting — wrapped in standard procedures. Our guide to clinical SOPs covers keeping that consistent under load.
As ever, the build-versus-partner decision turns on the regulated layer, which is slow to build and easy to get wrong. See our launch checklist for the full sequence and verification for restricted medicines for the safeguards.
How PExpo supports an allergy launch
PExpo provides the regulated layer — registered dispensing, prescriber governance, pharmacovigilance and the patient record — so a brand can launch a seasonal allergy service on a compliant base, with the referral limits and safety-netting that keep it defensible built into infrastructure designed to run them.
You bring the brand and the seasonal funnel; the higher-risk clinical elements are already handled. See our brand model for the scope and pricing for the commercials.
Allergy rewards operators who build for step-up care and honest referral limits rather than demand-led supply: match treatment to severity, keep the over-the-counter and prescribing lines clear, refuse what sits outside guidance, and escalate anaphylaxis and uncontrolled asthma. See our launch checklist and brand model for the operational detail.
Frequently asked questions
Can you treat hay fever online in the UK?
Yes. Much allergic rhinitis is managed with antihistamines and intranasal corticosteroids, many available over the counter, so a service adds value through assessment and step-up care. Prescribing is reserved for less-responsive cases, and anaphylaxis history or uncontrolled asthma should be referred rather than managed remotely.
Should a telehealth service offer steroid injections for hay fever?
Routine use of depot corticosteroid injections for hay fever is not recommended in UK guidance, because a systemic long-acting steroid's risk outweighs the benefit for a seasonal condition. A responsible service declines treatments that sit outside guidance, even when patients request and will pay for them.
When should allergy symptoms be referred rather than treated online?
A history of anaphylaxis, poorly controlled asthma alongside allergic rhinitis, and symptoms not responding to appropriate treatment are all signals to escalate to urgent or specialist care. Immunotherapy is a specialist service, not a remote add-on. Prescriber discretion applies.
